Compare Stocks → Seven unknown AI stocks that could DOMINATE the next six years. (From The Oxford Club) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:IMPLNASDAQ:KLDOTSE:PLINASDAQ:SNSE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMPLImpel Pharmaceuticals$0.27$0.02▼$4.20$956K1.17682,655 shs720,000 shsKLDOKaleido Biosciences$0.00$0.00▼$0.25$4K-0.063,499 shs60 shsPLIProMetic Life SciencesC$13.60C$7.13▼C$590.00C$317.06MN/A8,002 shs921 shsSNSESensei Biotherapeutics$1.36-2.9%$1.21$0.51▼$1.94$34.11M0.14137,670 shs161,783 shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMPLImpel Pharmaceuticals0.00%0.00%0.00%0.00%-97.04%KLDOKaleido Biosciences0.00%0.00%0.00%0.00%-50.00%PLIProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%SNSESensei Biotherapeutics-6.67%-7.28%+44.33%+83.22%-10.83%The 7th Trillion Dollar Company? (Ad)There are six American companies worth more than $1 trillion currently. But is there going to be a 7th trillion dollar company soon?This company just signed a MASSIVE deal with Apple.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMPLImpel PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/AN/AN/AN/APLIProMetic Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ASNSESensei Biotherapeutics4.405 of 5 stars3.55.00.04.80.61.71.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMPLImpel PharmaceuticalsN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/APLIProMetic Life SciencesN/AN/AN/AN/ASNSESensei Biotherapeutics3.00Buy$4.50230.88% UpsideCurrent Analyst RatingsLatest NCYT, SNSE, KLDO, IMPL, and PLI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2024SNSESensei BiotherapeuticsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$5.00(Data available from 5/22/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMPLImpel Pharmaceuticals$20.99M0.00N/AN/A($1.86) per share0.00KLDOKaleido Biosciences$1.10M0.00N/AN/AN/ANaNPLIProMetic Life SciencesC$39.91M0.00N/A3.94C$6.07 per share0.00SNSESensei BiotherapeuticsN/AN/AN/AN/A$2.33 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMPLImpel Pharmaceuticals-$106.31M-$3.13N/AN/AN/A-353.93%N/A-127.43%N/AKLDOKaleido BiosciencesN/A-$2.24N/AN/AN/AN/AN/AN/AN/APLIProMetic Life SciencesN/A-C$63.06N/AN/AN/AN/AN/AN/AN/ASNSESensei Biotherapeutics-$34.10M-$1.21N/AN/AN/AN/A-46.67%-40.88%8/1/2024 (Estimated)Latest NCYT, SNSE, KLDO, IMPL, and PLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024Q1 2024SNSESensei Biotherapeutics-$0.29-$0.32-$0.03-$0.32N/AN/A2/28/2024Q4 2023SNSESensei Biotherapeutics-$0.32-$0.30+$0.02-$0.30N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMPLImpel PharmaceuticalsN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/APLIProMetic Life SciencesN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMPLImpel PharmaceuticalsN/A0.190.13KLDOKaleido BiosciencesN/AN/AN/APLIProMetic Life Sciences37.474.063.66SNSESensei Biotherapeutics0.0112.0712.07OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMPLImpel Pharmaceuticals73.88%KLDOKaleido Biosciences81.56%PLIProMetic Life SciencesN/ASNSESensei Biotherapeutics10.50%Insider OwnershipCompanyInsider OwnershipIMPLImpel Pharmaceuticals6.20%KLDOKaleido Biosciences9.00%PLIProMetic Life SciencesN/ASNSESensei Biotherapeutics25.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableIMPLImpel Pharmaceuticals16023.90 million22.42 millionNot OptionableKLDOKaleido Biosciences7642.62 million38.79 millionNot OptionablePLIProMetic Life Sciences48723.31 millionN/ANot OptionableSNSESensei Biotherapeutics2825.08 million18.69 millionNot OptionableNCYT, SNSE, KLDO, IMPL, and PLI HeadlinesRecent News About These CompaniesMay 16, 2024 | americanbankingnews.comSensei Biotherapeutics (NASDAQ:SNSE) Research Coverage Started at StephensMay 14, 2024 | msn.comStephens & Co. Initiates Coverage of Sensei Biotherapeutics (SNSE) with Overweight RecommendationMay 13, 2024 | markets.businessinsider.comBuy Rating Justified for Sensei Biotherapeutics Amidst Strong Pipeline and Financial StabilityMay 9, 2024 | investorplace.comSNSE Stock Earnings: Sensei Biotherapeutics Misses EPS for Q1 2024May 9, 2024 | globenewswire.comSensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsApril 24, 2024 | globenewswire.comSensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual MeetingApril 9, 2024 | globenewswire.comSensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual ConferenceApril 4, 2024 | uk.investing.comSensei Biotherapeutics CFO Erin Colgan to resignApril 4, 2024 | globenewswire.comSensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor MicroenvironmentMarch 22, 2024 | globenewswire.comSensei Biotherapeutics to Participate in the 3rd Annual VISTA SymposiumMarch 6, 2024 | globenewswire.comSensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific ConferencesFebruary 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Sensei Biotherapeutics on Strong Fiscal Health and Promising Clinical TrialsFebruary 28, 2024 | globenewswire.comSensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business HighlightsFebruary 9, 2024 | msn.comSensei Biotherapeutics Announces Board Member Resignation and Consultant RoleFebruary 9, 2024 | msn.comSensei Biotherapeutics Streamlines Board, Appoints Interim ChairFebruary 7, 2024 | finance.yahoo.comSensei Biotherapeutics to Present at Upcoming ConferencesJanuary 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Sensei Biotherapeutics Amidst Promising SNS-101 Clinical Progress and Favorable Safety DataJanuary 4, 2024 | finance.yahoo.comSensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming MilestonesJanuary 1, 2024 | knoxdaily.comThe Potential Rise in the Price of Sensei Biotherapeutics Inc (SNSE) following insiders activityDecember 4, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Praxis Precision Medicines (PRAX) and Sensei Biotherapeutics (SNSE)New MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsImpel PharmaceuticalsNASDAQ:IMPLImpel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.Kaleido BiosciencesNASDAQ:KLDOKaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.ProMetic Life SciencesTSE:PLIPrometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.Sensei BiotherapeuticsNASDAQ:SNSESensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.